Receive The Newest Study Notifications

Collaboration Achieves First Significant Milestone with Successful Execution of Technology Transfer As the two organizations move closer to the commencement of the clinical trial to determine the safety and tolerability of the Apograft technology for bone marrow...

Pulmatrix, Inc. (NASDAQ: PULM) announces today that three sites in the United States have been activated for the Phase 2 clinical investigation for Pulmazole (PUR1900) – an inhaled iSPERSETMformulation of the anti-fungal drug itraconazole for the treatment of allergic...

The Alberta Diabetes Institute (ADI) will be at the center of a new clinical trial for an anti-obesity drug targeting people with rare genetic conditions that contribute to their obesity. Led by Andrea Haqq, clinical scientist at the ADI and associate professor in the...

Safety data from the first 90 patients will be presented Parametric evolution of the first (blinded) 33 patients that have been treated for 6 months will also be discussed MADRID, Spain and CAMBRIDGE, Mass., July 10, 2019 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A....

CStone Pharmaceuticals ("CStone", HKEX: 2616) today announced that the first patient has been dosed in China with avapritinib in the ongoing global Phase III VOYAGER clinical trial. This study is designed to evaluate the safety and efficacy of avapritinib as a...

 IntelGenx Corp. (IGX.V) (IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will present a Montelukast poster at the 12th edition of Clinical Trials on Alzheimer’s Disease (CTAD2019), to be held in San Diego, California, from December 4-7,...

- First patient dosed in Phase 3 trial evaluating efficacy and safety of maralixibat - Topline results expected in fourth quarter of 2020 Mirum Pharmaceuticals today announced the dosing of the first patient in the Phase 3 MARCH-PFIC clinical trial of its lead drug...

CMIC Group, a pioneer and a leading CRO (Contract Research Organizations) in Japan, is pleased to announce that the company joined Align Clinical CRO, a life sciences industry standards group dedicated to creating open technology standards that make it easier for...

Dermata Therapeutics, LLC, today announces positive results from a Phase 1 POC clinical trial of DMT410 (DMT310 + botulinum toxin (BTX)) for the treatment of primary axillary hyperhidrosis. These results provide evidence of Dermata's newly developed combination...

Trial will evaluate safety and efficacy of onvansertib plus FOLFIRI and Avastin® (bevacizumab) for treatment of patients with KRAS-mutated metastatic Colorectal Cancer (mCRC) Highly recognized unmet need for 50% of mCRC patients who harbor the KRAS mutation, given...

University of Alberta clinical researcher leading genetic study with drug trial to help patients with rare genetic disorders lose weight. The Alberta Diabetes Institute (ADI) will be at the centre of a new clinical trial for an anti-obesity drug targeting people with...

Equillium, Inc. (EQ), a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced it has initiated the EQUIP Phase 1b clinical trial of...

Tennessee’s innovative clinical trials network is soaring just one year into operations, bringing growing benefits for Tennesseans and the advancement of health care across the state. Launched in April 2018, the Clinical Trials Network of Tennessee (CTN2) has already...

 TARIS Bio™ today announced the dosing of the first patient in a Phase 1b clinical trial evaluating the investigational product TAR-200 in combination with Opdivo® (nivolumab), a programmed death-1 (PD-1) immune checkpoint inhibitor from Bristol-Myers Squibb. The...

 Kadmon Holdings, Inc. (KDMN) today announced that the first patient has been dosed in a Phase 2 clinical trial of KD025, the Company’s ROCK2 inhibitor, in patients with diffuse cutaneous systemic sclerosis (SSc). SSc is a chronic immune disorder characterized by...

Soliton, Inc. (SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced that the company has...

AG Mednet is delivering support to Median for its growing global portfolio of trials including its large programs in China. image credit- cfr.org French company Median Technologies, The Imaging Phenomics Company® and US based AG Mednet have renewed their partnership...

Placebo-controlled, multi-center trial will evaluate safety, tolerability and efficacy biomarkers to assess potential best-in-class FXR agonist Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to...

Vanderbilt-Ingram Cancer Center and GenomOncology LLC announce the launch of the newly redesigned and improved My Cancer Genome website. The new site showcases the breadth and depth of curated content from My Cancer Genome. Powered by GenomOncology's Precision...

Medical advances have dramatically increased the life expectancy of patients with sickle cell disease, but as patients are living longer, they are increasingly experiencing organ damage leading to early death. Now, researchers at the University of Pittsburgh and UPMC,...